| Parameter . | Baselinea . | Presentation . | Normal Range . |
|---|---|---|---|
| Blood glucose | 102 | 834 | 60–125 mg/dL |
| HbA1c | 5.4 | — | <6.5% |
| Sodium | 138 | 130 | 135–145 mmol/L |
| Potassium | 4.1 | 5.4 | 3.5–5 mmol/L |
| Chloride | 107 | 95 | 98–107 mmol/L |
| HCO3− | 23 | 4.8 | 22–26 mEq/L |
| Creatinine | 0.93 | 1.23 | 0.6–1.2 mg/dL |
| BUN | 19 | 35 | 7–20 mg/dL |
| Arterial pH | — | 7.08 | 7.35–7.45 |
| Beta-hydroxybutyrate | — | >8 | <0.5 mmol/L |
| Urine ketones | — | 8+ | Negative |
| GADA | — | 719 | <20 DK units |
| IAA | — | 0 | <0.01 |
| IA-2A | — | 0 | <5 DK units |
| ZnT8A | — | 0 | <0.02 |
| TG IgA | — | 0 | <0.05 |
| 21(OH) | — | 0.012 | <0.15 |
| Parameter . | Baselinea . | Presentation . | Normal Range . |
|---|---|---|---|
| Blood glucose | 102 | 834 | 60–125 mg/dL |
| HbA1c | 5.4 | — | <6.5% |
| Sodium | 138 | 130 | 135–145 mmol/L |
| Potassium | 4.1 | 5.4 | 3.5–5 mmol/L |
| Chloride | 107 | 95 | 98–107 mmol/L |
| HCO3− | 23 | 4.8 | 22–26 mEq/L |
| Creatinine | 0.93 | 1.23 | 0.6–1.2 mg/dL |
| BUN | 19 | 35 | 7–20 mg/dL |
| Arterial pH | — | 7.08 | 7.35–7.45 |
| Beta-hydroxybutyrate | — | >8 | <0.5 mmol/L |
| Urine ketones | — | 8+ | Negative |
| GADA | — | 719 | <20 DK units |
| IAA | — | 0 | <0.01 |
| IA-2A | — | 0 | <5 DK units |
| ZnT8A | — | 0 | <0.02 |
| TG IgA | — | 0 | <0.05 |
| 21(OH) | — | 0.012 | <0.15 |
21(OH), 21-hydroxylase antibody; BUN, blood urea nitrogen; GADA, glutamic acid decarboxylase antibody; IA-2A, islet antigen 2 antibody; IAA, insulin autoantibody; ZnT8A, zinc transporter 8 antibody; TG IgA, tissue transglutaminase IgA antibody.
Laboratory values are 1 wk before the first dose of PD-1 inhibitor therapy.
| Parameter . | Baselinea . | Presentation . | Normal Range . |
|---|---|---|---|
| Blood glucose | 102 | 834 | 60–125 mg/dL |
| HbA1c | 5.4 | — | <6.5% |
| Sodium | 138 | 130 | 135–145 mmol/L |
| Potassium | 4.1 | 5.4 | 3.5–5 mmol/L |
| Chloride | 107 | 95 | 98–107 mmol/L |
| HCO3− | 23 | 4.8 | 22–26 mEq/L |
| Creatinine | 0.93 | 1.23 | 0.6–1.2 mg/dL |
| BUN | 19 | 35 | 7–20 mg/dL |
| Arterial pH | — | 7.08 | 7.35–7.45 |
| Beta-hydroxybutyrate | — | >8 | <0.5 mmol/L |
| Urine ketones | — | 8+ | Negative |
| GADA | — | 719 | <20 DK units |
| IAA | — | 0 | <0.01 |
| IA-2A | — | 0 | <5 DK units |
| ZnT8A | — | 0 | <0.02 |
| TG IgA | — | 0 | <0.05 |
| 21(OH) | — | 0.012 | <0.15 |
| Parameter . | Baselinea . | Presentation . | Normal Range . |
|---|---|---|---|
| Blood glucose | 102 | 834 | 60–125 mg/dL |
| HbA1c | 5.4 | — | <6.5% |
| Sodium | 138 | 130 | 135–145 mmol/L |
| Potassium | 4.1 | 5.4 | 3.5–5 mmol/L |
| Chloride | 107 | 95 | 98–107 mmol/L |
| HCO3− | 23 | 4.8 | 22–26 mEq/L |
| Creatinine | 0.93 | 1.23 | 0.6–1.2 mg/dL |
| BUN | 19 | 35 | 7–20 mg/dL |
| Arterial pH | — | 7.08 | 7.35–7.45 |
| Beta-hydroxybutyrate | — | >8 | <0.5 mmol/L |
| Urine ketones | — | 8+ | Negative |
| GADA | — | 719 | <20 DK units |
| IAA | — | 0 | <0.01 |
| IA-2A | — | 0 | <5 DK units |
| ZnT8A | — | 0 | <0.02 |
| TG IgA | — | 0 | <0.05 |
| 21(OH) | — | 0.012 | <0.15 |
21(OH), 21-hydroxylase antibody; BUN, blood urea nitrogen; GADA, glutamic acid decarboxylase antibody; IA-2A, islet antigen 2 antibody; IAA, insulin autoantibody; ZnT8A, zinc transporter 8 antibody; TG IgA, tissue transglutaminase IgA antibody.
Laboratory values are 1 wk before the first dose of PD-1 inhibitor therapy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
